Efficacy and Tolerability of Duloxetine, a Novel Dual Reuptake Inhibitor, in the Treatment of Major Depressive Disorder

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 13, 2003, Pages 30-37

  Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR DEPRESSION; NAUSEA; NEUROTRANSMISSION; PAIN; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; VERTIGO; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; MULTICENTER STUDIES; NOREPINEPHRINE; PAIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS; THIOPHENES; TREATMENT OUTCOME;

EID: 0142043025     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36
2. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
3. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
4. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry 2002;63(suppl 5):13-16; discussion 23-25
5. Marangell LB, Johnson CR, Kertz B, et al. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry 2002;63:391-395
6. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. Psychopharmacology 1986;90: 131-138
7. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
8. Nelson JC. Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry 1998;59(suppl 5):65-68
9. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
10. Stahl SM. "Awakening" from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics [BRAINSTORM]. J Clin Psychiatry 1997;58:381-382
11. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001;76: 511-527
12. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
13. Pinder RM. Designing a new generation of antidepressant drugs. Acta Psychiatr Scand 1997;96(suppl 391):7-13
14. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880
15. Harvey AT, Rudolph RL, Preskom SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509
16. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 2001;62 (suppl 12):16-23
17. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-122
18. Lecrubier Y. Clinical utility of venlafaxine in comparison with other antidepressants. Int Clin Psychopharmacol 1995;10(suppl 2):29-35
19. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br J Psychiatry 2000;177:292-302
20. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59: 502-508
21. Preskom SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21
22. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000;40:161-167
23. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231
24. Stahl SM. Why settle for silver, when you can go for gold? response vs recovery as the goal of antidepressant therapy [BRAINSTORMS]. J Clin Psychiatry 1999;60:213-214
25. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):5-9
26. Rush AJ, Trivedi MH. Treating depression to remission. Psychiatr Ann 1995;25:704-709
27. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143: 18-23
28. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855
29. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287: 1840-1847
30. Goldstein DJ, Lu Y, Detke M, et al. Duloxetine vs paroxetine in the treatment of depression. Presented at the 155th annual meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa
31. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000;32:305-316
32. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
33. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23: 1296-1310
34. Wong DT. Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Invest Drugs 1998;7:1691-1699
35. Kornhuber J, Schultz A, Wiltfang J, et al. Persistence of haloperidol in human brain tissue. Am J Psychiatry 1999;156:885-890
36. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxefine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
37. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53
38. Gerber PD, Barrett JE, Barrett JA, et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med 1992;7:170-173
39. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relationship between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335
40. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400
41. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of the current literature. Harv Rev Psychiatry 2000;7:257-277
42. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30-36
43. Venlafaxine XR [package insert]. Collegeville, Pa: Wyeth-Ayerst; 2002
44. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
45. Berk M, du Plessis AD, Birkett M, et al, for the Lilly Duloxetine Depression Study Group. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Int Clin Psychopharmacol 1997;12:137-140